Page last updated: 2024-11-12

compound w

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

compound W: a 3,3'-diiodothyronine sulfate-like material in serum of pregnant women; a potential marker for fetal thyroid function [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16760376
CHEMBL ID1553155
CHEBI ID113561
SCHEMBL ID264541
MeSH IDM0357694

Synonyms (31)

Synonym
HMS3269J17
BRD-K98143539-001-01-4
AKOS015833412
compound w
3,5-bis(4-nitrophenoxy)benzoic acid
NCGC00167814-01
CHEBI:113561
B2120
173550-33-9
inchi=1/c19h12n2o8/c22-19(23)12-9-17(28-15-5-1-13(2-6-15)20(24)25)11-18(10-12)29-16-7-3-14(4-8-16)21(26)27/h1-11h,(h,22,23)
josxkpzxmvhrku-uhfffaoysa-
SCHEMBL264541
JOSXKPZXMVHRKU-UHFFFAOYSA-N
3,5-bis (4-nitrophenoxy) benzoic acid
methylesterl-lysinediisocyanate
CHEMBL1553155
Q27194457
DTXSID10587892
mfcd02093450
(3,5-bis(4-nitrophenoxy)benzoic acid)
AS-63608
J-010919
HMS3677N21
3,5-bis(4-nitrophenoxy)benzoic acid, 98%
HMS3413N21
compound-w
benzoic acid, 3,5-bis(4-nitrophenoxy)-
HY-103539
bisnitrophenoxybenzoicacid
CS-0028048
AKOS040745154

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dosing studies with three known inhibitors of Abeta production, sulindac sulfide (SSide), BMS-299897 ('897) and compound W (CW) are reported to demonstrate the utility and analytical characteristics of the assay."( Qualitative and quantitative characterization of the amyloid beta peptide (Abeta) population in biological matrices using an immunoprecipitation-LC/MS assay.
Cantone, JL; Drexler, DM; Ford, MJ; Meredith, JE; Polson, C; Toyn, JH, 2008
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's2 (28.57)29.6817
2010's1 (14.29)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.10 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index162.89 (26.88)
Search Engine Supply Index3.96 (0.95)

This Compound (54.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]